Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Knee surgery patients may skip hospital stay with anti-nausea drug

NCT ID NCT07639723

Symptom relief Sponsor: Endeavor Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding the nausea drug aprepitant to standard care helps more people having knee replacement surgery go home the same day. About 350 adults will receive either aprepitant plus usual anti-nausea medicines or a placebo plus usual care. The goal is to see if better nausea control reduces the need for an overnight hospital stay.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
aprepitant
What this could lead to
If it works, this could help more knee replacement patients avoid an overnight hospital stay by better controlling nausea and vomiting.
What could go wrong
This is a Phase 4 trial, but it has not started recruiting yet. The benefit may be small, and some patients may still need to stay overnight for other reasons.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Receiving primary, unilateral elective TKA with or without abductor canal block * Asa I-III * Age 18-90 * Ability to receive ondansetron and dexamethasone * Ability to consent and complete surveys * English or Spanish speaking * Receiving regional anesthesia (epidural or spinal) for surgery Exclusion Criteria: * Allergy to any of the anti-emetics being administered * Current treatment of pimozide * Emergent surgery * Revision/ multiple revisions of TKA * Clinical suspicion of possible bowel obstruction * Need for general anesthesia * Pregnant/breast feeding * AST\> 2.5 x the upper limit of normal or ALT\> 2.5 x upper limit of normal, bilirubin\> 1.5x upper limit of normal * Need for opioid or benzodiazepine antagonists * Not planned for same day discharge * Enrollment in a different drug trial for TKA * Unable to consent in English or Spanish

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PONV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Postoperative Nausea and Vomiting

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PONV

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Endeavor Health Skokie Hospital

    Skokie, Illinois, 60076, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.